Key result
Inclisiran could prevent ~1.6 million ASCVD events over 10 years in inadequately controlled adults.
Why the study?
Many patients do not reach recommended LDL-C levels on statins alone, and the potential eligibility and impact of inclisiran in the U.S. population were not quantified.
How many U.S. adults are eligible for inclisiran and how many ASCVD events could be prevented over 10 years with its use?
Cross-Sectional
How many U.S. adults are eligible for inclisiran and how many ASCVD events could be prevented over 10 years with its use?
Answers are grounded in this paper and cite their sources.
Broad application of inclisiran in eligible U.S. adults with inadequately controlled LDL-C on statins has the potential to prevent over 1.6 million ASCVD events over a 10-year period.
BACKGROUND: Many patients do not reach recommended low-density lipoprotein cholesterol (LDL-C) levels on statins alone. Inclisiran is a small interfering RNA providing ∼50% further reduction in LDL-C. OBJECTIVES: The authors estimated the number of U.S. adults eligible for inclisiran and the number of preventable atherosclerotic cardiovascular disease (ASCVD) events with inclisiran use. METHODS: Using a cross-sectional study of the National Health and Nutrition Examination Survey 2011 to 2020, the authors identified 3 cohorts: high-risk primary prevention (≥20% 10-year ASCVD risk or 7.5% to <20% with ≥2 risk-enhancing factors), diabetes, and secondary prevention. Included adults were ≥18 years with LDL-C ≥70 mg/dL (≥55 mg/dL if very high-risk for ASCVD events) despite statin therapy. The ASCVD Pooled Cohort Equation and SMART2 risk score were used to estimate ASCVD events in 10 years "without inclisiran." Preventable ASCVD events were calculated "with inclisiran" using inclisiran trial data to estimate LDL-C reduction and Cholesterol Treatment Trialists' data to estimate reductions in ASCVD events per mmol/L of LDL-C. RESULTS: Among the high-risk primary prevention, diabetes, and secondary prevention cohorts, the authors estimated 5.4 million, 6.5 million, and 8.0 million U.S. adults, respectively, to be eligible for inclisiran. Based on 34.5%, 29.0%, and 29.0% respective risk reductions, the authors estimated ∼448,600, ∼459,800, and ∼711,000 ASCVD events could be prevented over 10 years with inclisiran. Most preventable ASCVD events occurred among males and White patients. CONCLUSIONS: Approximately 20 million U.S. adults with inadequately controlled LDL-C may be eligible for inclisiran, with the potential to prevent over 1.6 million ASCVD events over 10 years.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2026) conducted a cross-sectional in Inadequately controlled LDL-C. Inclisiran vs. Without inclisiran was evaluated on Preventable ASCVD events in 10 years. An estimated 20 million U.S. adults with inadequately controlled LDL-C are eligible for inclisiran, which has the potential to prevent over 1.6 million ASCVD events over 10 years.
Synapse has enriched 10 related papers. Consider them for comparative context: